Lisa Cassidy
Cardiovascular Disease · Newark, NJNPI 1790753457
Payments from drug & device makers
Across 142 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$630
- Boehringer Ingelheim$232
- Lilly USA, LLC$226
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$151
- Otsuka America Pharmaceutical, Inc.$108
- AstraZeneca$96
- plus $691 from 15 others
What the payments were for
- Food & beverage$2,133100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $630 |
| Boehringer Ingelheim | 16 | $232 |
| Lilly USA, LLC | 14 | $226 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $151 |
| Otsuka America Pharmaceutical, Inc. | 7 | $108 |
| AstraZeneca | 6 | $96 |
| Amarin Pharma, Inc. | 7 | $92 |
| Pfizer | 6 | $91 |
| AbbVie | 6 | $91 |
| Bayer | 3 | $56 |
| Seqirus USA Inc | 3 | $46 |
| GSK | 3 | $45 |
| Amgen | 3 | $44 |
| Johnson & Johnson | 3 | $43 |
| Exact Sciences | 2 | $38 |
| Edwards Lifesciences | 1 | $38 |
| Merck | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $24 |
| Novartis | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$2,133 in reported general payments places this provider in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $65,473 |
| EliquisApixaban | 24 | $23,001 |
| Levothyroxine Sodium | 94 | $2,081 |
| Metoprolol Succinate | 72 | $1,821 |
| Rosuvastatin Calcium | 58 | $1,167 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 15 | $1,015 |
| Losartan Potassium | 58 | $886 |
| Valsartan | 31 | $872 |
| Omeprazole | 55 | $872 |
| Atorvastatin Calcium | 55 | $833 |
| Quetiapine Fumarate | 34 | $812 |
| Trazodone Hcl | 43 | $770 |
| Pantoprazole Sodium | 38 | $754 |
| SynthroidLevothyroxine Sodium | 13 | $648 |
| Azelastine Hcl | 25 | $632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $630 | $65,47342 claims |
| PfizerEliquis | $91 | $23,00124 claims |
| AbbVieSynthroid | $91 | $64813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Newark
- Marc CohenNewark$1M
- Muhamed SaricNewark$159K
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Jasjit WaliaElizabeth$859K
- Sajjad SabirCamden$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.